DermTech Performance
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and DermTech are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days DermTech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, DermTech is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more
| Begin Period Cash Flow | 77.8 M |
DermTech |
DermTech Relative Risk vs. Return Landscape
If you would invest (100.00) in DermTech on December 13, 2024 and sell it today you would earn a total of 100.00 from holding DermTech or generate -100.0% return on investment over 90 days. DermTech is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than DermTech, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
DermTech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DermTech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DermTech, and traders can use it to determine the average amount a DermTech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| DMTK |
Based on monthly moving average DermTech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DermTech by adding DermTech to a well-diversified portfolio.
DermTech Fundamentals Growth
DermTech Stock prices reflect investors' perceptions of the future prospects and financial health of DermTech, and DermTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DermTech Stock performance.
| Return On Equity | -1.22 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (5.33) % | |||
| Current Valuation | 15.43 M | |||
| Shares Outstanding | 34.96 M | |||
| Price To Earning | (139.70) X | |||
| Price To Book | 0.02 X | |||
| Price To Sales | 0.21 X | |||
| Revenue | 15.3 M | |||
| EBITDA | (97.89 M) | |||
| Cash And Equivalents | 173.79 M | |||
| Cash Per Share | 5.78 X | |||
| Total Debt | 54.39 M | |||
| Debt To Equity | 0.14 % | |||
| Book Value Per Share | 1.14 X | |||
| Cash Flow From Operations | (76.98 M) | |||
| Earnings Per Share | (2.65) X | |||
| Total Asset | 121.93 M | |||
| Retained Earnings | (423.94 M) | |||
| Current Asset | 140.61 K | |||
| Current Liabilities | 446.54 K | |||
Things to note about DermTech performance evaluation
Checking the ongoing alerts about DermTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DermTech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DermTech is not yet fully synchronised with the market data | |
| DermTech has some characteristics of a very speculative penny stock | |
| DermTech has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 15.3 M. Net Loss for the year was (100.89 M) with profit before overhead, payroll, taxes, and interest of 647 K. | |
| DermTech currently holds about 173.79 M in cash with (76.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78. |
- Analyzing DermTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DermTech's stock is overvalued or undervalued compared to its peers.
- Examining DermTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DermTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of DermTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DermTech's stock. These opinions can provide insight into DermTech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in DermTech Stock
If you are still planning to invest in DermTech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the DermTech's history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |